Although these clinical results have shown that PTX markedly lowers the levels of glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) and may ameliorate liver histopathological changes in NASH patients, further large and well-designed studies are necessary to confirm the observed effects20. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.